Cui Y - Search Results

1

A clinical decision support system to predict the efficacy for EGFR-TKIs based on artificial neural network.

Liang X, Guan R, Zhu J, Meng Y, Zhu J, Yang Y, Cui Y, Dai J, Mao W, Lv L, Shen D, Guo R. Liang X, et al. Among authors: cui y. J Cancer Res Clin Oncol. 2023 Oct;149(13):12265-12274. doi: 10.1007/s00432-023-05104-3. Epub 2023 Jul 11. J Cancer Res Clin Oncol. 2023. PMID: 37434091

2

Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.

Zhang C, Cao H, Cui Y, Jin S, Gao W, Huang C, Guo R. Zhang C, et al. Among authors: cui y. Thorac Cancer. 2021 Oct;12(19):2574-2584. doi: 10.1111/1759-7714.14141. Epub 2021 Sep 12. Thorac Cancer. 2021. PMID: 34510760 Free PMC article.

3

Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.

Cui Y, Liu X, Wu Y, Liang X, Dai J, Zhang Z, Guo R. Cui Y, et al. Front Oncol. 2022 Mar 10;12:798401. doi: 10.3389/fonc.2022.798401. eCollection 2022. Front Oncol. 2022. PMID: 35359393 Free PMC article.

4

Association of KDR mutation with better clinical outcomes in pan-cancer for immune checkpoint inhibitors.

Cui Y, Zhang P, Liang X, Xu J, Liu X, Wu Y, Zhang J, Wang W, Zhang F, Guo R. Cui Y, et al. Am J Cancer Res. 2022 Apr 15;12(4):1766-1783. eCollection 2022. Am J Cancer Res. 2022. PMID: 35530271 Free PMC article.

5

Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR-TKIs in advanced non-small cell lung cancer: A systematic review and network meta-analysis.

Dai J, Liu X, Li J, Qu T, Cui Y, Jin S, Zhang E, Guo R. Dai J, et al. Among authors: cui y. Thorac Cancer. 2023 Feb;14(6):535-543. doi: 10.1111/1759-7714.14783. Epub 2023 Jan 2. Thorac Cancer. 2023. PMID: 36594109 Free PMC article. Review.

6

LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer.

Dai J, Qu T, Yin D, Cui Y, Zhang C, Zhang E, Guo R. Dai J, et al. Among authors: cui y. Cell Death Dis. 2023 May 8;14(5):312. doi: 10.1038/s41419-023-05840-x. Cell Death Dis. 2023. PMID: 37156816 Free PMC article.

7

B4GALT1 promotes immune escape by regulating the expression of PD-L1 at multiple levels in lung adenocarcinoma.

Cui Y, Li J, Zhang P, Yin D, Wang Z, Dai J, Wang W, Zhang E, Guo R. Cui Y, et al. J Exp Clin Cancer Res. 2023 Jun 12;42(1):146. doi: 10.1186/s13046-023-02711-3. J Exp Clin Cancer Res. 2023. PMID: 37303063 Free PMC article.

8

Concomitant genomic features stratify prognosis to patients with advanced EGFR mutant lung cancer.

Liang X, Xu J, Jiang Y, Yan Y, Wu H, Dai J, Cui Y, Zhang C, Chen W, Zhang Z, Guo R. Liang X, et al. Among authors: cui y. Mol Carcinog. 2024 Sep;63(9):1643-1653. doi: 10.1002/mc.23750. Epub 2024 Jun 11. Mol Carcinog. 2024. PMID: 38860603

9

Leveraging mitochondrial-programmed cell death dynamics to enhance prognostic accuracy and immunotherapy efficacy in lung adenocarcinoma.

Zhang L, Cui Y, Zhou G, Zhang Z, Zhang P. Zhang L, et al. Among authors: cui y. J Immunother Cancer. 2024 Oct 24;12(10):e010008. doi: 10.1136/jitc-2024-010008. J Immunother Cancer. 2024. PMID: 39455097 Free PMC article.

10

Identification of gene signatures relevant to the efficacy of immune checkpoint inhibitors in non-small cell lung cancer.

Liu M, Li Q, Meng X, Cui Y, Sun W, Wang H, Gao Q. Liu M, et al. Among authors: cui y. Medicine (Baltimore). 2024 Dec 6;103(49):e40569. doi: 10.1097/MD.0000000000040569. Medicine (Baltimore). 2024. PMID: 39654181 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18,537 results

Search Page

Filters